Aspira Women's Health Inc.

06/17/2026 | Press release | Distributed by Public on 06/17/2026 14:28

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Aspira Women's Health Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). As of the close of business on the record date for the Annual Meeting, there were 43,500,411 shares of the Company's common stock, par value $0.001 per share, issued and outstanding and entitled to vote. There were 27,144,522 shares present in person or by proxy at the Annual Meeting, or 62.40%, constituting a quorum. The final voting results were as follows:

Proposal 1: Election of Directors

The Company's stockholders elected each of the Company's six nominees for director for a one-year term expiring at the Company's 2026 annual meeting of stockholders and until their successors are elected and qualified, as set forth below:

NOMINEE

FOR

AGAINST

ABSTENTIONS

BROKER NON-VOTES

Ellen Beausang

5,989,004

327,224

34,689

16,569,699

Jeffrey Cohen, M.D.

5,990,548

325,667

34,702

16,569,699

John Fraser

6,278,119

38,109

34,689

16,569,699

Cynthia Hundorfean

5,991,040

325,188

34,689

16,569,699

Winfred Parnell, M.D.

5,989,187

327,040

34,690

16,569,699

Jane Pine Wood

​

​

5,983,931

​

​

​

332,046

​

​

​

34,940

​

​

​

16,569,699

​

Proposal 2: Advisory Vote to Approve the Compensation of the Company's Named Executive Officers

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2026, as set forth below:

FOR

AGAINST

ABSTENTIONS

BROKER NON-VOTES

5,568,783

505,829

276,305

16,569,699

Proposal 3: Approval of an Amendment to the Aspira Women's Health Inc. 2019 Stock Incentive Plan

The Company's stockholders approved an amendment to the Company's 2019 Stock Incentive Plan (the "2019 Plan") to increase the number of shares of common stock authorized to be granted under the 2019 Plan by 5,000,000 shares so that a total of 9,532,818 shares of common stock are authorized to be granted under the 2019 Plan, as set forth below:

FOR

AGAINST

ABSTENTIONS

BROKER NON-VOTES

5,654,497

624,233

72,187

16,569,699

Proposal 4: Ratification of the Selection of the Company's Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection of BDO USA, P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2026, as set forth below:

FOR

AGAINST

ABSTENTIONS

BROKER NON-VOTES

22,810,174

15,244

95,198

0

​

​

​

​

​

​

​

Aspira Women's Health Inc. published this content on June 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 17, 2026 at 20:28 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]